Combination antihypertension therapy: The “underresearched” combinations

Decrease of blood pressure (BP) and its maintenance on target level is the main factor for cardiovascular mortality and morbidity reduction in hypertensive patients. For effective BP decrease most patients need combination therapy. The article is focused on benefits and adverse events of some combinations. In details an issue considered, on the combination of beta-blocker and renin-angiotensine-aldosteron system blocker, which, by the data from Russian observational programs, is the leader among two-component combinations. © 2017, Silicea-Poligraf, All right reserved.

Авторы
Kotovskaya Y.V. 1, 2 , Runikhina N.K.2 , Ostapenko V.S.2
Издательство
Silicea-Poligraf
Номер выпуска
5
Язык
Русский
Страницы
132-139
Статус
Опубликовано
Том
145
Год
2017
Организации
  • 1 Peoples’ Friendship University of Russia, Moscow, Russian Federation
  • 2 N. I. Pirogov Russian National Research Medical University (RNRMU), Russian Gerontology Scientific-Clinical Center, Moscow, Russian Federation
Ключевые слова
Adverse events; Arterial hypertension; Combination therapy
Дата создания
19.10.2018
Дата изменения
19.10.2018
Постоянная ссылка
https://repository.rudn.ru/ru/records/article/record/5825/
Поделиться

Другие записи